J.W.R. Nortier

10.8k citations

157 papers · 7.8k indexed · 2 hit papers · h-index 44

Impact in

Hematology top 0.5%
- Erythropoietin and Anemia Treatment
- Iron Metabolism and Disorders
Oncology top 0.5%
- Cancer survivorship and care
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research

Papers in

Oncology 87
- Cancer Treatment and Pharmacology 27
- Cancer survivorship and care 19
- HER2/EGFR in Cancer Research 11
- Global Cancer Incidence and Screening 8
Cancer Research 47
- Breast Cancer Treatment Studies 43

Co-authors: Hans Gelderblom Timothy J. Littlewood Hein Putter Bernardo L. Rapoport Els Vercammen Emilio Bajetta Judith R. Kroep Cornelis J.�H. van de Velde
Journals: Journal of Clinical Oncology (17 papers)European Journal of Cancer (15 papers)Breast Cancer Research and Treatment (14 papers)Annals of Oncology (11 papers)The Breast (8 papers)
Partner nations: Netherlands United States United Kingdom

In The Last Decade

J.W.R. Nortier

156 papers receiving 7.6k citations

Hit Papers

align trajectories log scale

The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients 2004 · 678 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2004 European Journal of Cancer
2001 Journal of Clinical Oncology

Peers

Countries citing papers authored by J.W.R. Nortier

Since Specialization

Citations

This map shows the geographic impact of J.W.R. Nortier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.W.R. Nortier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.W.R. Nortier more than expected).

Fields of papers citing papers by J.W.R. Nortier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.W.R. Nortier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.W.R. Nortier. The network helps show where J.W.R. Nortier may publish in the future.

Co-authors

The 25 scholars most cited alongside J.W.R. Nortier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J.W.R. Nortier Line = papers co-authored together J.W.R. Nortier links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial Journal of Clinical Oncology ·S.B. Vliek, Iris Noordhoek, Elma Meershoek‐Klein Kranenbarg, Annelot G.J. van Rossum, Vincent O. Dezentjé, Agnes Jager, J.W. Esmeralda Hokken, Hein Putter, Annette W.G. van der Velden, Mathijs P. Hendriks, Sandra D. Bakker, Yvonne E A van Riet, Vivianne C. G. Tjan‐Heijnen, Johanneke E.A. Portielje, Judith R. Kroep, J.W.R. Nortier, Cornelis J.�H. van de Velde, Sabine C. Linn	2022	8
2	Monitoring quality of life in Dutch women with breast cancer: The Care Notebook study Annals of Oncology ·Rieneke T. Lugtenberg, Maarten J. Fischer, FE de Jongh, Kenichi Inoue, Ayako Matsuda, S.R.S. Ramai, J.W.R. Nortier, Hein Putter, Kazue Yamaoka, Kiyoshi Kubota, Keigo Kobayashi, Ad A. Kaptein, Judith R. Kroep	2018	1
3	The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study BMC Cancer ·Stefanie de Groot, Maaike P.G. Vreeswijk, Marij J.P. Welters, Gido Gravesteijn, J.J.W.A. Boei, Anouk Jochems, Daniel Houtsma, Hein Putter, Jacobus JM van der Hoeven, J.W.R. Nortier, Hanno Pijl, Judith R. Kroep	2015	173
4	Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients The Breast ·Melissa Kool, D.B.Y. Fontein, Elma Meershoek‐Klein Kranenbarg, J.W.R. Nortier, Emiel J. Rutgers, Perla J. Marang‐van de Mheen, Cornelis J.�H. van de Velde	2015	15
5	Stick Together: A Nordic Walking Group Intervention for Breast Cancer Survivors Journal of Psychosocial Oncology ·Maarten J. Fischer, Elly MM Krol-Warmerdam, G. Ranke, Henricus M. Vermeulen, Joke Van der Heijden, J.W.R. Nortier, Adrian A. Kaptein	2015	20
6	Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy Molecular Cancer Therapeutics ·Wendy Onstenk, Jaco Kraan, Bianca Mostert, Mieke M. Timmermans, Ayoub Charehbili, Vincent T.H.B.M. Smit, Judith R. Kroep, J.W.R. Nortier, Saskia van de Ven, Joan B. Heijns, Lonneke W. Kessels, Hanneke W.M. van Laarhoven, Monique M.E.M. Bos, Cornelis J.�H. van de Velde, Jan W. Gratama, Anieta M. Sieuwerts, John W.M. Martens, John A. Foekens, Stefan Sleijfer	2014	47
7	Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment Cancer Research ·Eveline M. Dijkgraaf, Moniek Heusinkveld, Bart Tummers, Lisa T.C. Vogelpoel, Renske Goedemans, Veena Jha, J.W.R. Nortier, Marij J.P. Welters, Judith R. Kroep, Sjoerd H. van der Burg	2013	286
8	Clinical and pathological response after neoadjuvant chemotherapy with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer European Journal of Cancer ·Ayoub Charehbili, Saskia van de Ven, Gerrit‐Jan Liefers, Vincent T.H.B.M. Smit, Martin N.J.M. Wasser, Elma Meershoek‐Klein Kranenbarg, A. Elise van Leeuwen‐Stok, Cornelis J.�H. van de Velde, J.W.R. Nortier, Judith R. Kroep	2013	1
9	Tumor stroma ratio as a predictor for response to neoadjuvant chemotherapy (TAC) in breast cancer (BC) : A Dutch Breast Cancer Trialists' Group (BOOG) side-study European Journal of Cancer ·T.J.A. Dekker, Ayoub Charehbili, Vincent T.H.B.M. Smit, Elma Meershoek‐Klein Kranenbarg, R.A.E.M. Tollenaar, Cornelis J.�H. van de Velde, Gerrit‐Jan Liefers, J.W.R. Nortier, Wilma E. Mesker, Judith R. Kroep	2013	1
10	Oncologists’ practice and attitudes regarding fertility preservation in female cancer patients: a pilot study in the Netherlands Journal of Psychosomatic Obstetrics & Gynecology ·Leoni A. Louwé, Moniek M. ter Kuile, Carina G. J. M. Hilders, Esther Jenninga, Sanne M. Tiemessen, Alexander A.W. Peters, J.W.R. Nortier, Anne M. Stiggelbout	2013	22
11	CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial Breast Cancer Research and Treatment ·Vincent O. Dezentjé, Hans Gelderblom, Ron H. N. van Schaik, J. M. Vletter-Bogaartz, Tahar van der Straaten, Judith A.M. Wessels, Elma Meershoek‐Klein Kranenbarg, Els M.J.J. Berns, Caroline Seynaeve, Hein Putter, Cornelis J.�H. van de Velde, J.W.R. Nortier, Henk‐Jan Guchelaar	2013	11
12	Impact of scalp cooling on chemotherapy-induced alopecia, wig use and hair growth of patients with cancer European Journal of Oncology Nursing ·Corina van den Hurk, M. Elske van den Akker‐van Marle, W.P.M. Breed, Lonneke V. van de Poll‐Franse, J.W.R. Nortier, J.W.W. Coebergh	2013	33
13	Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor–Positive Breast Cancer Obstetrical & Gynecological Survey ·W. van de Water, Christos Markopoulos, Cornelis J.�H. van de Velde, Caroline Seynaeve, Annette Hasenburg, Daniel Rea, Hein Putter, J.W.R. Nortier, Anton J.M. de Craen, E.T.M. Hille, Esther Bastiaannet, Peyman Hadji, Rudi G. J. Westendorp, Gerrit‐Jan Liefers, Stephen E. Jones	2012	21
14	Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer Current Pharmaceutical Design ·Eveline M. Dijkgraaf, Marij J.P. Welters, J.W.R. Nortier, Sjoerd H. van der Burg, Judith R. Kroep	2012	55
15	Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer – A TEAM study analysis European Journal of Cancer ·W. van de Water, D.B.Y. Fontein, Johanna G. H. van Nes, John M.S. Bartlett, E.T.M. Hille, Hein Putter, Tammy Robson, Gerrit‐Jan Liefers, Rudi M. H. Roumen, Caroline Seynaeve, Luc Dirix, Robert Paridaens, Elma Meershoek‐Klein Kranenbarg, J.W.R. Nortier, Cornelis J.�H. van de Velde	2012	21
16	Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer Cancer Treatment Reviews ·Saskia van de Ven, Vincent T.H.B.M. Smit, Tim Dekker, J.W.R. Nortier, Judith R. Kroep	2010	175
17	Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer. PubMed ·Judith R. Kroep, Sabine C. Linn, Epie Boven, Haiko J. Bloemendal, Jara M. Baas, IAM Mandjes, (unknown), W. M. Smit, H. de Graaf, C.P. Schröder, G. J. Vermeulen, W. C. J. Hop, J.W.R. Nortier	2010	13
18	In Vitro Schedule-Dependent Interaction Between Melphalan and Oxaliplatin in Human Colorectal Cancer Cell Lines Journal of Surgical Research ·L.B.J. van Iersel, Tamara M. Koudijs, Ellen J. Hoekman, Connie M. Janssen‐van Rhijn, Alexander L. Vahrmeijer, J.W.R. Nortier, Cornelis J.�H. van de Velde, Hans Gelderblom, Peter J.K. Kuppen	2009	12
19	Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer Annals of Oncology ·Geke A.P. Hospers, Michael Schaapveld, J.W.R. Nortier, J. Wils, Aart van Bochove, Robert S. de Jong, G.J. Creemers, Z. Erjavec, D. J. de Gooyer, P. H. Th. J. Slee, C J Gerrits, Jeff M. Smit, Nanno H. Mulder	2006	29
20	CBO-richtlijn 'behandeling van het mammacarcinoom' Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank ·Emiel J. Rutgers, J.W.R. Nortier, M.K. Tuut, Geertjan van Tienhoven, H. Struikmans, M. Bontenbal, M.F. von Meyenfeldt, Gerard Vreugdenhil, Tineke Benraadt, Bert Garssen, J.L. Peterse	2002	38

About J.W.R. Nortier

J.W.R. Nortier is a scholar working on Oncology, Cancer Research, Geriatrics and Gerontology, Family Practice and Genetics, having authored 157 papers that have together received 7.8k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (43 papers), Estrogen and related hormone effects (36 papers), Cancer Treatment and Pharmacology (27 papers), Cancer survivorship and care (19 papers), HER2/EGFR in Cancer Research (11 papers), Pharmacogenetics and Drug Metabolism (9 papers), Frailty in Older Adults (8 papers) and Global Cancer Incidence and Screening (8 papers). The work is most often cited by research in Hematology (1.5k citations), Oncology (3.5k citations), Cancer Research (1.9k citations), Geriatrics and Gerontology (440 citations) and Biochemistry (391 citations). J.W.R. Nortier has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Hans Gelderblom, Timothy J. Littlewood, Hein Putter, Bernardo L. Rapoport, Els Vercammen, Emilio Bajetta, Judith R. Kroep, Cornelis J.�H. van de Velde, Caroline Seynaeve and Henk‐Jan Guchelaar. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Breast Cancer Research and Treatment, Annals of Oncology and The Breast.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact